A combination drug, ZMAb, is composed of equal parts of 3 mouse monoclonal antibodies, directed against the envelope glycoproteins of the Ebola virus. The pioneering work was conducted at the National Microbiology Laboratory, Winnipeg, Canada, through the Public Health Agency of Canada (PHAC). In completed primate studies using a highly lethal challenge, the ZMAb was able to provide 100% treatment survival when administered 1 day after challenge and 50% treatment survival when given 2 days after challenge (3). Further, ZMAb treatment resulted in low viral loads, mild symptoms and no viral shedding of the challenge agent.

Defyrus has an exclusive option to license this technology from PHAC, and is currently exercising an exclusive license. Our pilot GLP and cGMP manufactured needs for ZMAb are being met by the Biotechnology Research Institute of the National Research Council of Canada in Montreal. Larger scale manufacturing contracts are under discussion to address commercial scale production to meet Public Health and Biodefense needs.